Final survival data from HERIZON-GEA-01 reinforce TEVIMBRA and ZIIHERA regimen

BeOne reported new overall survival results from the second planned interim analysis and the formal final analysis of the Phase 3 HERIZON-GEA-01 trial, which it says further support the benefit of adding TEVIMBRA to ZIIHERA and chemotherapy as a first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma. The update follows the earlier topline and first-interim readouts and arrives after the U.S. approval of this regimen. For holders, the update matters because it extends the survival evidence behind a label that BeOne is now commercializing.

1. Announcement dated October 23, 2026, per the Benzinga France report that carried the release.
2. Covers the second interim analysis (IA2) and the formal final analysis of the Phase 3 HERIZON-GEA-01 trial.
3. Trial compares ZIIHERA plus chemotherapy, with and without TEVIMBRA, against trastuzumab plus chemotherapy in first-line HER2-positive advanced or metastatic GEA.
4. Earlier first-interim data reported median overall survival of 26.4 months for the TEVIMBRA-containing arm versus 19.2 months for the control arm.
5. Median progression-free survival was 12.4 months in the ZIIHERA-containing arms versus 8.1 months in the control arm (first-interim data).